Graham Capital Management L.P. Has $1.12 Million Stake in Pediatrix Medical Group, Inc. $MD

Key Points

• Graham Capital Management L.P. increased its stake in Pediatrix Medical Group by 119.0% in the first quarter, acquiring a total of 77,309 shares worth approximately $1.12 million.
• Brokerages have given Pediatrix Medical Group a consensus rating of "Moderate Buy" with an average target price of $16.75, with Zacks Research upgrading their rating to "strong-buy."
• Pediatrix Medical Group reported $0.53 earnings per share (EPS) for the latest quarter, exceeding analysts' expectations and reflecting a 7.1% decline in revenue compared to the previous year.

Graham Capital Management L.P. boosted its holdings in shares of Pediatrix Medical Group, Inc. (NYSE:MD - Free Report) by 119.0% in the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 77,309 shares of the company's stock after purchasing an additional 42,010 shares during the quarter. Graham Capital Management L.P. owned about 0.09% of Pediatrix Medical Group worth $1,120,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in the business. California State Teachers Retirement System boosted its stake in Pediatrix Medical Group by 0.9% during the 4th quarter. California State Teachers Retirement System now owns 80,327 shares of the company's stock valued at $1,054,000 after purchasing an additional 752 shares during the period. AlphaQuest LLC boosted its stake in Pediatrix Medical Group by 16.0% during the 1st quarter. AlphaQuest LLC now owns 5,877 shares of the company's stock valued at $85,000 after purchasing an additional 811 shares during the period. SummerHaven Investment Management LLC boosted its stake in Pediatrix Medical Group by 0.9% during the 1st quarter. SummerHaven Investment Management LLC now owns 112,327 shares of the company's stock valued at $1,628,000 after purchasing an additional 1,028 shares during the period. Natixis Advisors LLC boosted its stake in Pediatrix Medical Group by 8.1% during the 1st quarter. Natixis Advisors LLC now owns 19,156 shares of the company's stock valued at $278,000 after purchasing an additional 1,435 shares during the period. Finally, GAMMA Investing LLC boosted its stake in Pediatrix Medical Group by 219.5% during the 1st quarter. GAMMA Investing LLC now owns 2,569 shares of the company's stock valued at $37,000 after purchasing an additional 1,765 shares during the period. Institutional investors own 97.71% of the company's stock.

Pediatrix Medical Group Price Performance

Shares of Pediatrix Medical Group stock traded up $0.02 during midday trading on Tuesday, hitting $16.97. 130,106 shares of the company were exchanged, compared to its average volume of 756,333. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.80 and a quick ratio of 1.80. The firm has a market cap of $1.48 billion, a P/E ratio of 13.12 and a beta of 1.29. Pediatrix Medical Group, Inc. has a 52 week low of $10.29 and a 52 week high of $17.67. The firm has a 50 day simple moving average of $14.51 and a 200-day simple moving average of $14.12.

Pediatrix Medical Group (NYSE:MD - Get Free Report) last posted its earnings results on Tuesday, August 5th. The company reported $0.53 EPS for the quarter, topping the consensus estimate of $0.42 by $0.11. The business had revenue of $468.84 million during the quarter, compared to the consensus estimate of $464.37 million. Pediatrix Medical Group had a return on equity of 18.94% and a net margin of 5.66%.Pediatrix Medical Group's revenue was down 7.1% on a year-over-year basis. During the same quarter last year, the company earned $0.34 EPS. Research analysts forecast that Pediatrix Medical Group, Inc. will post 1.38 earnings per share for the current year.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on MD. Leerink Partners increased their target price on Pediatrix Medical Group from $14.50 to $17.00 and gave the company a "market perform" rating in a research note on Friday. UBS Group raised their price objective on Pediatrix Medical Group from $16.00 to $16.50 and gave the stock a "neutral" rating in a research report on Thursday, August 14th. Finally, Zacks Research upgraded Pediatrix Medical Group to a "strong-buy" rating in a research report on Monday, August 11th. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and five have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $16.79.

Pediatrix Medical Group Profile

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.